Health & Biotech

Danish pharma giant Novo Nordisk rose 24.9% after licensing its Parkinson's cell therapy to AI-native biotech Cellular Intelligence and shutting its internal program. NVIDIA's BioNeMo platform is consolidating as the dominant AI backbone for global drug R&D, with Eli Lilly and Thermo Fisher signing co-innovation lab agreements. The FDA granted Fast Track designation to the AI-partnered cell therapy, signaling regulatory acceptance of AI-assisted pipelines worldwide.

NVIDIA's BioNeMo platform is consolidating AI drug discovery globally, anchoring partnerships with Eli Lilly and Thermo Fisher while Danish giant Novo Nordisk offloads disease areas to AI-native developers. The emerging three-layer stack — compute, foundation models, application biotech — is reshaping pharmaceutical R&D from Copenhagen to California, compressing decade-long timelines.

Novo Nordisk posted a Q1 2026 earnings beat and a 24.9% stock surge while outsourcing its Parkinson's disease programs to AI partner Cellular Intelligence. NVIDIA's BioNeMo platform is the infrastructure enabling this shift, with Lilly and Thermo Fisher also building R&D strategies around it. Big Pharma is converting internal research costs to variable platform partnerships at accelerating pace.

Denmark's Novo Nordisk licensed its Parkinson's cell therapy program to AI-native firm Cellular Intelligence and closed its internal cell therapy unit entirely. NVIDIA's BioNeMo platform meanwhile secured partnerships with Thermo Fisher and Eli Lilly, cementing its position as the backbone of global pharmaceutical AI infrastructure. The moves reflect a widening industry pattern: large drugmakers worldwide are outsourcing experimental modalities to AI specialists rather than building capability i

NVIDIA's BioNeMo platform is now operational backbone for AI drug discovery across global pharmaceutical companies. Novo Nordisk's stock rose 25% in 30 days after shifting to a licensing-first AI strategy, closing its internal cell therapy unit. Five competing AI biotech platforms launched in rapid succession, all running on NVIDIA compute.

US biotech REGENXBIO is on course to commercialise RGX-202, its gene therapy for Duchenne Muscular Dystrophy, by 2027 after completing enrolment in its pivotal trial ahead of schedule. With top-line data expected in early Q2 2026 and a US regulatory filing planned for mid-year, the therapy's cleaner safety profile positions it as a serious rival to the only currently approved DMD gene therapy. The programme also has implications for the estimated 300,000 DMD patients worldwide who have historica